Sino Biopharmaceutical Limited

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
2.34 ^HKD	-3.70%		-14.29%	-32.56%

Apr. 19	Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	MT
Apr. 17	Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	MT

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

August 23, 2022 at 05:23 am EDT

Sino Biopharmaceutical Limited announced interim cash dividend of HKD 0.06 per share for the period ended 30 June 2022. Scheduled dates are as follows: Ex-dividend date 06 September 2022, Record date 09 September 2022 and Payment date 28 September 2022.

Latest news about Sino Biopharmaceutical Limited

Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	Apr. 19	MT
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	Apr. 17	MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	Apr. 10	MT
Sino Biopharmaceutical Trustee Repurchases Shares	Apr. 08	MT
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	Apr. 08	MT
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China	Apr. 07	CI
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023	Mar. 29	MT
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024	Mar. 28	CI
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China	Mar. 24	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection	Mar. 24	CI
Sino Biopharmaceutical's Developing Two Drugs for MASH	Mar. 15	MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy	Mar. 15	MT
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"	Mar. 15	CI
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR	Mar. 14	MT
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet	Mar. 13	CI
Hong Kong Shares Slump Amid Chinese Growth Concerns	Mar. 05	MT
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart	Feb. 28	CI
Sino Biopharmaceutical's Anti-Cancer Drug Under Priority Review in China	Feb. 07	MT
Sino Biopharm Units Sell 67% Stake in Pharmaceutical Company	Feb. 06	MT
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 million	Feb. 06	RE
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical Co., Ltd from Sino Biopharmaceutical Limited for CNY 1.8 billion.	Feb. 05	CI
Sino Biopharmaceutical Files for Chinese Launch of Obeticholic Acid Tablets	Feb. 01	MT
China Outlook, Profit-Taking Roil Asian Stock Markets	Jan. 24	MT
Sino Biopharmaceutical Repurchases Over 78 Million Shares Under Buyback Plan	Jan. 24	MT

Chart Sino Biopharmaceutical Limited

Duration

Period

More charts

Company Profile

Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).

Sector

Pharmaceuticals

Calendar

2024-06-10 - Final dividend

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biopharmaceutical Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.163 CNY

Average target price

4.32 CNY

Spread / Average Target

+99.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SINO BIOPHARMACEUTICAL LIMITED	-32.56%	5.69B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals